Victor Euzen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Victor Euzen has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Maxime Wack
Ophtalmopôle, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France
6 shared publications - Anne Auperin
Gustave Roussy 4 Biostatistics and Epidemiology Office Inserm U1018 Oncostat, Ligue Contre le Cancer, University Paris-Saclay, Villejuif, France
5 shared publications - Anne-Laure Gaultier
Department of Radiology, European Georges Pompidou Hospital, Paris, France
5 shared publications - Aurelien Marabelle
University of Paris Saclay, Gustave Roussy Cancer Center, Villejuif, France
5 shared publications - Bastien Rance
Hôpital Européen Georges Pompidou
5 shared publications - Benjamin Morin
Hôpital Européen Georges-Pompidou (HEGP) 8 , Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France
5 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S8 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Supplementary Figure S1-S8 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S8 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Supplementary Figure S1-S8 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Definition of viral genomic status groups
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Definition of viral genomic status groups
- 15 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4434-4447
HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Purpose: A subset of patients with human papillomavirus (HPV)–positive oropharyngeal squamous cell carcinoma (OPSCC) develops disease recurrence despite generally favorable outcomes. Reliable biomarkers for risk stratification remain lacking. We investigated whether comprehensive viral genomic profiling refines prognostic classification. Experimental Design: Tumor samples from 100 patients with p16-positive and HPV DNA–positive OPSCC enrolled in 2 independent cohorts were analyzed using targeted viral capture sequencing. Viral genotype, sublineage, single-nucleotide variation, virus–host integration sites, viral structural variants (SV), clonality, and viral copy number were characterized. Associations with cumulative incidence of progression, progression-free survival (PFS), and overall survival were assessed at 60 months. Results: HPV16 was detected in 94 tumors, 83 of which belonged to the HPV16_A1 sublineage. Within this sublineage, 20 tumors harbored strictly episomal viral genomes, whereas 63 exhibited integration and/or viral SV. No progression events occurred in the strictly episomal HPV16_A1 subgroup, whereas 12 occurred among HPV16_A1 tumors with an integration and/or SV. At 60 months, no progression events were observed in strictly episomal HPV16_A1 tumors compared with a 23.1% cumulative incidence of progression in HPV16_A1 tumors with an integration and/or SV. Previously reported high-risk single-nucleotide variants and a novel upstream regulatory region variant were associated with worse PFS. Integration sites were enriched in open chromatin and promoter regions and clustered within viral E2 and E4 genes. Conclusions: Within HPV16_A1 tumors, viral genomic architecture defines clinically distinct subgroups. Strictly episomal (wild-type) genomes identify a low-risk population, whereas integration and SV characterize higher-risk disease.
- 15 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4434-4447
HPV16 Genomic Status Stratifies Risk of Disease Recurrence in Oropharyngeal Squamous Cell Carcinoma
Purpose: A subset of patients with human papillomavirus (HPV)–positive oropharyngeal squamous cell carcinoma (OPSCC) develops disease recurrence despite generally favorable outcomes. Reliable biomarkers for risk stratification remain lacking. We investigated whether comprehensive viral genomic profiling refines prognostic classification. Experimental Design: Tumor samples from 100 patients with p16-positive and HPV DNA–positive OPSCC enrolled in 2 independent cohorts were analyzed using targeted viral capture sequencing. Viral genotype, sublineage, single-nucleotide variation, virus–host integration sites, viral structural variants (SV), clonality, and viral copy number were characterized. Associations with cumulative incidence of progression, progression-free survival (PFS), and overall survival were assessed at 60 months. Results: HPV16 was detected in 94 tumors, 83 of which belonged to the HPV16_A1 sublineage. Within this sublineage, 20 tumors harbored strictly episomal viral genomes, whereas 63 exhibited integration and/or viral SV. No progression events occurred in the strictly episomal HPV16_A1 subgroup, whereas 12 occurred among HPV16_A1 tumors with an integration and/or SV. At 60 months, no progression events were observed in strictly episomal HPV16_A1 tumors compared with a 23.1% cumulative incidence of progression in HPV16_A1 tumors with an integration and/or SV. Previously reported high-risk single-nucleotide variants and a novel upstream regulatory region variant were associated with worse PFS. Integration sites were enriched in open chromatin and promoter regions and clustered within viral E2 and E4 genes. Conclusions: Within HPV16_A1 tumors, viral genomic architecture defines clinically distinct subgroups. Strictly episomal (wild-type) genomes identify a low-risk population, whereas integration and SV characterize higher-risk disease.
- 12 September 2024
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 62 (10)
Evaluation of an in-house pan-Malassezia quantitative PCR in human clinical samples
Althought Malassezia spp. have been involved in various pathologies, they are integral part of the cutaneous, gut, oral, ears, nose and throat (ENT) mycobiota. Since Malassezia are difficult to grow in culture, unexhaustive molecular biology methods have been developed to detect them. The aim of the study was to evaluate an in-house pan-Malassezia quantitative PCR (panM-qPCR) on various clinical human samples and determine Malassezia burden in various human mycobiota. The panM-qPCR was designed to target the repeated 28S rDNA gene from all Malassezia species. We used the assay to quantify the Malassezia burden on 361 samples from 161 subjects (80 skin swabs from 10 healthy volunteers (HV), 13 samples from 2 seborrheic dermatitis patients (SD), 90 skin samples from 19 burned patients, 119 stools samples from 89 immunocompromised patients, 59 ENT samples from 41 patients). For HV, the amount of Malassezia was different according to the swabbed areas. Cq in SD are lower than in HV. In burned patients, Cq was significantly lower compared to HV. In stool samples, 6.7% were positive for Malassezia spp. with a high Cq. For the ENT area, a higher proportion of positive specimens were detected in ears samples than in nose samples. Our findings emphasized the importance of qPCR, confirming elevated Malassezia spp. levels on individuals' faces and scapls, increased burden in SD patients and in severely burnt patients than in HV. The pan-MqPCR appears to be a promising tool for studying Malassezia in various human mycobiota. Malassezia species are ubiquitous members of various human mycobiomes, including cutaneous and mucosal sites. While these fungi have been implicated in several pathologies, their presence as commensals complicates their study, especially due to difficulties in culturing them in vitro. This has necessitated the development of molecular techniques to detect and quantify Malassezia species directly from clinical samples.
- 12 September 2024
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 62 (10)
Evaluation of an in-house pan-Malassezia quantitative PCR in human clinical samples
Althought Malassezia spp. have been involved in various pathologies, they are integral part of the cutaneous, gut, oral, ears, nose and throat (ENT) mycobiota. Since Malassezia are difficult to grow in culture, unexhaustive molecular biology methods have been developed to detect them. The aim of the study was to evaluate an in-house pan-Malassezia quantitative PCR (panM-qPCR) on various clinical human samples and determine Malassezia burden in various human mycobiota. The panM-qPCR was designed to target the repeated 28S rDNA gene from all Malassezia species. We used the assay to quantify the Malassezia burden on 361 samples from 161 subjects (80 skin swabs from 10 healthy volunteers (HV), 13 samples from 2 seborrheic dermatitis patients (SD), 90 skin samples from 19 burned patients, 119 stools samples from 89 immunocompromised patients, 59 ENT samples from 41 patients). For HV, the amount of Malassezia was different according to the swabbed areas. Cq in SD are lower than in HV. In burned patients, Cq was significantly lower compared to HV. In stool samples, 6.7% were positive for Malassezia spp. with a high Cq. For the ENT area, a higher proportion of positive specimens were detected in ears samples than in nose samples. Our findings emphasized the importance of qPCR, confirming elevated Malassezia spp. levels on individuals' faces and scapls, increased burden in SD patients and in severely burnt patients than in HV. The pan-MqPCR appears to be a promising tool for studying Malassezia in various human mycobiota. Malassezia species are ubiquitous members of various human mycobiomes, including cutaneous and mucosal sites. While these fungi have been implicated in several pathologies, their presence as commensals complicates their study, especially due to difficulties in culturing them in vitro. This has necessitated the development of molecular techniques to detect and quantify Malassezia species directly from clinical samples.
- Open Access
- 22 July 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (3) , 107281
Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant
- 22 July 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (3) , 107281
Open AccessZanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant
- 30 June 2022
- Published by JLE in Annales de biologie clinique
- Vol. 80 (3) , 294-300
Résumés de la 5
- Open Access
- 19 October 2021
- Published by Elsevier in EBioMedicine
- Vol. 73, 103637
Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study
- 19 October 2021
- Published by Elsevier in EBioMedicine
- Vol. 73, 103637
Open AccessRelease of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study